ImmunoPrecise Selects LifeSci Advisors as Investor Relations Agent of Record

LifeSci Advisors provides life science companies comprehensive solutions to communications and investor outreach.

ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease

Talem Therapeutics has advanced development of candidate panel TATX-112, against an undisclosed target, into formal lead candidate characterization.

ImmunoPrecise Identifies a Unique Antibody, 23-H7, That Demonstrates In Vivo Efficacy, an Alternative Mechanism of Action and Binds all Tested SARS-CoV-2 Variants of Concern

23-H7 binds to all tested variants of concern and blocks the RBD/ACE2 binding interaction indirectly through an alternative mechanism of action

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter of 2021 Fiscal Year

Increase in gross profit and expansion in research and development initiatives

ImmunoPrecise Antibodies Announces Results from a Comprehensive Screening of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies

The Screening Addresses Potential Approaches to Treating Emerging and Future Variants of SARS-CoV-2 Through Multi-Antibody Combination Therapy

Items 1 to 6 of 137 total

Show per page